Research output per year
Research output per year
Personal profile
Headline
PROFESSOR | Medicine, Liver Diseases
Biography
Dr. Kim-Schluger is the Associate Director of The Recanati/Miller Transplantation Institute and was named the Sydney J. Zweig Professor of Medicine. Dr. Kim -Schluger's expertise is the management of liver transplant recipients, as well as on the natural course and treatment of hepatitis C. Among her research efforts have been studies that named to identify different treatment options for patients with hepatitis C virus infection; to better understand the course of hepatitis C after liver transplantation and to determine the best immunosuppressive drug regimens for liver transplant recipients. Dr. Kim-Schluger also has a special interest in the controversial issues and ethical dilemmas of organ allocation.
Fingerprint
Dive into the research topics where Hyung Leona Kim-Schluger is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Extensive Health Care Utilization and Costs of an Early Liver Transplantation Program for Alcoholic Hepatitis
Im, G. Y., Vogel, A. S., Florman, S., Nahas, J., Friedman, S. L., Aqui, S., Ford, L., Mirza, O., Kim-Schluger, L. & Schiano, T. D., Jan 2022, In: Liver Transplantation. 28, 1, p. 27-38 12 p.Research output: Contribution to journal › Article › peer-review
5 Scopus citations -
Recurrent Liver Allograft Injury in Patients With Donor-Derived Malignancy Treated With Immunosuppression Cessation and Retransplantation
Lee, B. T., Ganjoo, N., Fiel, M. I., Hechtman, J. F., Sarkar, S. A., Kim-Schluger, L., Florman, S. S. & Schiano, T. D., 1 Aug 2022, In: American Journal of Clinical Pathology. 158, 2, p. 199-205 7 p.Research output: Contribution to journal › Article › peer-review
-
Two hundred and fifty-one right hepatectomies for living donation: Association between preoperative risk factors, hepatic dysfunction, and complications
Mahamid, A., Fenig, Y., Amodeo, S., Kozato, A., Facciuto, M., Ahmad, J., Kim-Schluger, L., Florman, S., Schiano, T. & Facciuto, M., Jul 2022, In: Surgery. 172, 1, p. 397-403 7 p.Research output: Contribution to journal › Article › peer-review
-
Early Liver Transplantation for Severe Alcoholic Hepatitis in the United States - A Single-Center Experience
Im, G. Y., Kim-Schluger, L., Shenoy, A., Schubert, E., Goel, A., Friedman, S. L., Florman, S. & Schiano, T. D., 1 Mar 2016, In: American Journal of Transplantation. 16, 3, p. 841-849 9 p.Research output: Contribution to journal › Article › peer-review
Open Access157 Scopus citations -
Hepatic decompensation/serious adverse events in post-liver transplantation recipients on sofosbuvir for recurrent hepatitis C virus
Patel, N., Bichoupan, K., Ku, L., Yalamanchili, R., Harty, A., Gardenier, D., Ng, M., Motamed, D., Khaitova, V., Bach, N., Chang, C., Grewal, P., Bansal, M., Agarwal, R., Liu, L., Im, G., Leong, J., Kim-Schluger, L., Odin, J., Ahmad, J., & 5 others, 7 Mar 2016, In: World Journal of Gastroenterology. 22, 9, p. 2844-2854 11 p.Research output: Contribution to journal › Article › peer-review
Open Access4 Scopus citations
Press / Media
-
The $35 billion race to cure a liver disease that affects 30 million Americans
16/12/19
1 item of Media coverage
Press/Media
-
David Moyer: From the wastewater pond to the kitchen table
16/05/19
1 item of Media coverage
Press/Media
-
NASH: The Next Big, Fatty Drug for the Pharmaceutical Industry
9/05/19
1 item of Media coverage
Press/Media
-
Merck Licenses NASH Compound from NGM Biopharma for $20 Million
3/01/19
1 item of Media coverage
Press/Media
-
The $35 billion race to cure a liver disease that affects 30 million Americans
30/12/18 → 31/12/18
3 items of Media coverage
Press/Media